We are skilled at finding senior executives and experts, renowned scientists, clinicians and researchers worldwide, and assessing them from both a leadership and scientific perspective.
Whether you are a start-up, an established corporation, or a CDMO, working on pre-clinical or clinical development, or commercialisation, we’ll help you build collaborative teams. We are skilled in customising our approach to attract diverse, globally-experienced leaders for science-driven environments.
New business models require collaborative approaches to pipeline innovation, manufacturing and supply, and myriad bench-to-bedside translations. This matrix of layered initiatives requires leaders at all levels of the organisation to be capable of cutting across traditional disciplines through influence, persuasion and compromise.
Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.
When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.
Big data collection and usage; digitalization; and artificial intelligence in the entire life-cycle of therapies, from development to the point of patient access, are unstoppable trends. Wielding these technology tools in a meaningful way requires innovation leadership that is balanced by well-defined change management skills and a keen ability to prioritise.
Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.
When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.
SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix (imlifidase) from Hansa Biopharma for a total of €115m ($133.6m). The deal covers the European Union, Iceland, Liechtenstein, Norway, Switzerland, the UK, and the Middle East and North Africa (MENA) region.
Gilead Sciences has concluded its acquisition of Tubulis, a Germany-based biotechnology company developing next-generation antibody-drug conjugates (ADCs), in a transaction valued at up to $5bn. First announced last month, the move aims to advance Gilead’s oncology portfolio.
Lonza, a global contract development and manufacturing organization (CDMO), and Bristol Myers Squibb, a global pharmaceutical company, recently announced an exclusive single-target licensing agreement. Under the terms of this agreement, BMS will gain exclusive access to the SYNtecan linker-payload platform to advance an ADC against an undisclosed target.
